These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6669934)

  • 1. Absorption and excretion of azodisal sodium and its metabolites in man after rectal administration of a single 2-g dose.
    Sandberg-Gertzén H; Ryde M; Järnerot G
    Scand J Gastroenterol; 1983 May; 18(4):571-5. PubMed ID: 6669934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy.
    Sandberg-Gertzén H; Ryde M; Järnerot G
    Scand J Gastroenterol; 1983 Jan; 18(1):107-11. PubMed ID: 6675167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion.
    Campieri M; Lanfranchi GA; Boschi S; Brignola C; Bazzocchi G; Gionchetti P; Minguzzi MR; Belluzzi A; Labò G
    Gut; 1985 Apr; 26(4):400-5. PubMed ID: 3979912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biliary excretion of olsalazine sodium in humans.
    Ryde M; Gustavsson S
    Eur J Drug Metab Pharmacokinet; 1987; 12(1):17-24. PubMed ID: 3609069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
    Rijk MC; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1988 Jan; 23(1):107-12. PubMed ID: 2894070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers.
    Rijk MC; van Hogezand RA; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1989 Dec; 24(10):1179-85. PubMed ID: 2574905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is N-acetylation of 5-aminosalicylic acid reversible in man?
    Meese CO; Fischer C; Klotz U
    Br J Clin Pharmacol; 1984 Oct; 18(4):612-5. PubMed ID: 6487501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food.
    Ryde EM; Ahnfelt NO
    Eur J Clin Pharmacol; 1988; 34(5):481-8. PubMed ID: 3203708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
    Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
    Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time.
    Christensen LA; Slot O; Sanchez G; Boserup J; Rasmussen SN; Bondesen S; Hansen SH; Hvidberg EF
    Br J Clin Pharmacol; 1987 Mar; 23(3):365-9. PubMed ID: 3567055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of 5-aminosalicylic acid after jejunal instillation in man.
    Haagen Nielsen O; Bondesen S
    Br J Clin Pharmacol; 1983 Dec; 16(6):738-40. PubMed ID: 6661362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats.
    Shafii A; Chowdhury JR; Das KM
    Am J Gastroenterol; 1982 May; 77(5):297-9. PubMed ID: 6123257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oroileal transit of slow release 5-aminosalicylic acid.
    Goebell H; Klotz U; Nehlsen B; Layer P
    Gut; 1993 May; 34(5):669-75. PubMed ID: 8504969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
    Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission.
    Almer S; Norlander B; Ström M; Osterwald H
    Scand J Gastroenterol; 1991 Mar; 26(3):327-35. PubMed ID: 1853156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa.
    Bondesen S; Tage-Jensen U; Jacobsen O; Hansen SH; Rasmussen SN; Hvidberg EF
    Eur J Clin Pharmacol; 1986; 31(1):23-6. PubMed ID: 2877884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.
    Willoughby CP; Aronson JK; Agback H; Bodin NO; Truelove SC
    Gut; 1982 Dec; 23(12):1081-7. PubMed ID: 7173720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA).
    De Mey C; Meineke I
    Br J Clin Pharmacol; 1992 Feb; 33(2):179-82. PubMed ID: 1550697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.